| Oncology meets immunology: the cancer-immunity cycle DS Chen, I Mellman immunity 39 (1), 1-10, 2013 | 6308 | 2013 |
| Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients RS Herbst, JC Soria, M Kowanetz, GD Fine, O Hamid, MS Gordon, ... Nature 515 (7528), 563-567, 2014 | 5345 | 2014 |
| Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial A Rittmeyer, F Barlesi, D Waterkamp, K Park, F Ciardiello, J Von Pawel, ... The Lancet 389 (10066), 255-265, 2017 | 4623 | 2017 |
| Elements of cancer immunity and the cancer–immune set point DS Chen, I Mellman Nature 541 (7637), 321-330, 2017 | 4225 | 2017 |
| TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells S Mariathasan, SJ Turley, D Nickles, A Castiglioni, K Yuen, Y Wang, ... Nature 554 (7693), 544-548, 2018 | 3740 | 2018 |
| Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial L Fehrenbacher, A Spira, M Ballinger, M Kowanetz, J Vansteenkiste, ... The Lancet 387 (10030), 1837-1846, 2016 | 2856 | 2016 |
| MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer T Powles, JP Eder, GD Fine, FS Braiteh, Y Loriot, C Cruz, J Bellmunt, ... Nature 515 (7528), 558-562, 2014 | 2589 | 2014 |
| VEGF in signaling and disease: beyond discovery and development RS Apte, DS Chen, N Ferrara Cell 176 (6), 1248-1264, 2019 | 1825 | 2019 |
| Top 10 challenges in cancer immunotherapy PS Hegde, DS Chen Immunity 52 (1), 17-35, 2020 | 1416 | 2020 |
| Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma DF McDermott, MA Huseni, MB Atkins, RJ Motzer, BI Rini, B Escudier, ... Nature medicine 24 (6), 749-757, 2018 | 1023 | 2018 |
| Molecular pathways: next-generation immunotherapy—inhibiting programmed death-ligand 1 and programmed death-1 DS Chen, BA Irving, FS Hodi Clinical cancer research 18 (24), 6580-6587, 2012 | 714 | 2012 |
| Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma JJ Wallin, JC Bendell, R Funke, M Sznol, K Korski, S Jones, G Hernandez, ... Nature communications 7 (1), 1-8, 2016 | 636 | 2016 |
| Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure) JM Kim, DS Chen Annals of Oncology 27 (8), 1492-1504, 2016 | 588 | 2016 |
| T cells use two directionally distinct pathways for cytokine secretion M Huse, BF Lillemeier, MS Kuhns, DS Chen, MM Davis Nature immunology 7 (3), 247-255, 2006 | 496 | 2006 |
| An optimized optogenetic clustering tool for probing protein interaction and function A Taslimi, JD Vrana, D Chen, S Borinskaya, BJ Mayer, MJ Kennedy, ... Nature communications 5 (1), 4925, 2014 | 367 | 2014 |
| Molecular biomarker analyses using circulating tumor cells EA Punnoose, SK Atwal, JM Spoerke, H Savage, A Pandita, RF Yeh, ... PloS one 5 (9), e12517, 2010 | 366 | 2010 |
| Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy FS Hodi, M Ballinger, B Lyons, JC Soria, M Nishino, J Tabernero, ... Journal of Clinical Oncology 36 (9), 850-858, 2018 | 320 | 2018 |
| Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy M Mayoux, A Roller, V Pulko, S Sammicheli, S Chen, E Sum, C Jost, ... Science translational medicine 12 (534), eaav7431, 2020 | 289 | 2020 |
| A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. RS Herbst, MS Gordon, GD Fine, JA Sosman, JC Soria, O Hamid, ... Journal of Clinical Oncology 31 (15_suppl), 3000-3000, 2013 | 287 | 2013 |
| A systemic complete response of metastatic melanoma to local radiation and immunotherapy SM Hiniker, DS Chen, S Reddy, DT Chang, JC Jones, JA Mollick, ... Translational oncology 5 (6), 404-407, 2012 | 255 | 2012 |
Priti HegdeFoundation MedicineVerified email at foundationmedicine.com
